GSK plc (LON:GSK) Receives Average Rating of "Moderate Buy" from Analysts

GSK plc (LON:GSK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is GBX 1,842.50 ($23.89).

GSK has been the topic of several recent research reports. Citigroup lowered their price objective on shares of GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a "buy" rating on the stock in a research note on Friday, July 5th. Shore Capital reiterated a "buy" rating on shares of GSK in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,850 ($23.99) target price on shares of GSK in a report on Tuesday, September 3rd. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a report on Monday, July 29th. Finally, Berenberg Bank reiterated a "buy" rating and issued a GBX 1,820 ($23.60) target price on shares of GSK in a report on Tuesday, September 10th.

GSK Price Performance

Shares of GSK traded down GBX 14.50 ($0.19) during mid-day trading on Thursday, hitting GBX 1,392.50 ($18.06). The company's stock had a trading volume of 10,677,450 shares, compared to its average volume of 10,394,940. The firm has a 50-day moving average price of GBX 1,545.31 and a 200 day moving average price of GBX 1,594.75. The stock has a market capitalization of £56.81 billion, a price-to-earnings ratio of 1,232.30, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a fifty-two week low of GBX 1,371.40 ($17.78) and a fifty-two week high of GBX 1,823.50 ($23.65).

GSK Dividend Announcement

The business also recently announced a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be given a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK's payout ratio is 5,309.73%.

Insider Buying and Selling at GSK

In other news, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the business's stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average cost of GBX 2,051 ($26.60) per share, for a total transaction of £9,147.46 ($11,862.87). In other news, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average price of GBX 2,051 ($26.60) per share, with a total value of £9,147.46 ($11,862.87). Also, insider Jonathan Symonds purchased 7,150 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($18.08) per share, with a total value of £99,671 ($129,258.20). Insiders purchased 7,604 shares of company stock valued at $10,893,886 in the last quarter. Company insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.